India Glycols Investor Presentation for Q2 & H1FY26
India Glycols announces Q2 & H1FY26 results with revenue and profit growth. Restructuring is proposed through demerger of business into separate entities.
The financial results indicate stable growth. The restructuring could have a significant impact but depends on execution and regulatory approvals.
The announcement highlights positive financial performance in Q2 and H1, including revenue and profit growth. The proposed restructuring could unlock value for stakeholders.
* India Glycols Limited has released its investor presentation for Q2 & H1FY26. * Q2FY26 Consolidated Financials: * Gross Revenue: ₹2,412 crore, up by 13%. * Net Revenue: ₹1,092 crore, up by 14%. * EBITDA: ₹160 crore, up by 33%; EBITDA Margin at 14.6% vs. 12.4%. * PAT: ₹65 crore, up by 31%; PAT Margin at 5.9% vs. 5.1%. * H1FY26 Consolidated Financials: * Gross Revenue: ₹4,916 crore, up by 11%. * Net Revenue: ₹2,133 crore, up by 11%. * EBITDA: ₹311 crore, up by 25%; EBITDA Margin at 14.6% vs. 12.8%. * PAT: ₹138 crore, up by 26%; PAT Margin at 6.5% vs. 5.7%. * Segment-wise Performance: * Bio-Fuel (BF): Q2FY26 revenue at ₹423 crore, up 62.9% YoY; H1FY26 revenue at ₹770 crore, up 54.5% YoY. * Potable Spirits (PS): Q2FY26 revenue at ₹338 crore, up 24.5% YoY; H1FY26 revenue at ₹680 crore, up 23.4% YoY. * Bio-Based Specialties and Performance Chemicals (BSPC): Q2FY26 revenue at ₹288 crore; H1FY26 revenue at ₹588 crore. * Ennature Biopharma (EB): Q2FY26 revenue at ₹43 crore; H1FY26 revenue at ₹94 crore. * Other Highlights: * Equity shares increased due to stock split on August 12, 2025. * Shareholders approved raising funds through preferential allotment in EGM held on November 12, 2025. * Proposed Restructuring: Demerger of Potable Spirits & Bio-fuel and Bio-pharma Businesses into separate entities – ISL and EBL respectively
What to do with a filing like this
India Glycols Limited filed this with the NSE as a statutory disclosure, categorised under investor presentation. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by India Glycols Limited. Read the original for the full detail.